Townsend Richard Nolan 4
4 · Lexeo Therapeutics, Inc. · Filed Dec 12, 2024
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-12-10−2,500→ 118,655 totalExercise: $2.33Exp: 2031-02-15→ Common Stock (2,500 underlying) - Exercise/Conversion
Common Stock
2024-12-10$2.33/sh+2,500$5,825→ 123,195 total - Sale
Common Stock
2024-12-10$8.20/sh−2,500$20,491→ 120,695 total
Footnotes (4)
- [F1]The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $7.98 to $8.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- [F4]25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.